65,437 trials
Diabetes · Diabetes Mellitus, Type 1
Primary: Glycosylated Haemoglobin (HbA1c) for Full Analysis Set (Pregnant Subjects) at GW 36 — 6.27; 6.33 Percent (%) glycosylated haemoglobin — p=0.400
Heart Failure
Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants
Rheumatoid Arthritis
Primary: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 — 288; 85 Participants — p=<0.001
Migraine Disorders · Migraine
Primary: Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper — -3.8; -3.6; -3.8; -3.3 Migraine…
Schizophrenia
Primary: Change in Positive And Negative Syndrome Scale (PANSS) Total Score From Baseline to Endpoint — -38.37; -37.24 scores on a scale — p=0.784
Multiple Myeloma
Primary: Number of Days With Progression Free Survival (PFS) — 1166; 519 Days
Healthy
Primary: AUC0-t — 1139.3; 1115.6; 1065.3 μg*hr/mL
Gout
Primary: Uric Acid (mg/dL) — 1.33; 1.91; 5.06; 9.76 mg/dL
Hepatitis C, Chronic · Liver Cirrhosis
Primary: Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response) — 41; 40; 21 Participants
Hyperlipidemia · Healthy
Primary: Gene Expression Changes — 841; 1041; 1639; 628 number of regulated genes
Pain
Primary: Length of Action — 6.63; 7.02; 7.48; 7.16 minutes — p=0.359
Chronic Stable Angina
Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025
Pancreatic Disease
Primary: Endoscopic Sample
Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category — 19; 6; 5; 0 participants
Bipolar Depression
Primary: Change in the Children Depression Rating Scale, Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57) — -29.6; -27.3 Scores on a scale